Immune Cells Gained Inflammation Potential; MS Not Studied
By MS Buddy ·
Summarized from Immunity, Nov 2024 · PubMed. AI-generated summary. Not medical advice.
Lab study · immune cells studied in the lab
Research by Davide Mangani, Ana Anderson and 15 colleagues at Gene Lay Institute of Immunology and Inflammation, Harvard T.H. Chan School of Public Health and 2 other institutions in the United States.
What makes some immune cells more likely to drive inflammation?
Key Takeaway
Removing a natural brake from immune cells made them more likely to drive inflammation in lab tests, but the study did not examine MS.

What They Found
Researchers studied how certain immune cells shift toward a state that can drive inflammation. An immune signal lowered a natural brake in these cells. Removing that brake made the cells more likely to drive inflammation, even without that signal. Keeping the brake active reduced their potential to drive inflammation. The brake also attached to another part of the cells involved in this shift.
Who Should Care and Why
This lab study examined immune cells, not people with MS. It focused on cells that can either support normal tissue functions or drive inflammation. The findings help explain what controls that difference. The abstract discusses inflammatory diseases broadly, without naming MS as a condition studied. It does not show whether this process occurs in people with MS.
Important Considerations
You cannot tell from this study whether changing these cells would help people with MS. The abstract does not report a human study or a treatment test. It also does not give a sample size.
AI-generated summary — for informational purposes only, not medical advice
Read the original abstract
Published in Immunity by et al.. Reproduced from the PubMed record.
T helper (Th) 17 cells encompass a spectrum of cell states, including cells that maintain homeostatic tissue functions and pro-inflammatory cells that can drive autoimmune tissue damage. Identifying regulators that determine Th17 cell states can identify ways to control tissue inflammation and restore homeostasis. Here, we found that interleukin (IL)-23, a cytokine critical for inducing pro-inflammatory Th17 cells, decreased transcription factor T cell factor 1 (TCF1) expression. Conditional deletion of TCF1 in mature T cells increased the pro-inflammatory potential of Th17 cells, even in the absence of IL-23 receptor signaling, and conferred pro-inflammatory potential to homeostatic Th17 cells. Conversely, sustained TCF1 expression decreased pro-inflammatory Th17 potential. Mechanistically, TCF1 bound to RORγt, thereby interfering with its pro-inflammatory functions, and orchestrated a regulatory network that determined Th17 cell state. Our findings identify TCF1 as a major determinant of Th17 cell state and provide important insight for the development of therapies for Th17-driven inflammatory diseases.
Categories
Explore more research
Related MS research

11/16/2026
A planned study will use detailed brain scans and blood tests to explore why relapsing-remitting MS
Read More
11/15/2026
In tissue from mice with an MS-like disease, a lab drug reduced excess chemical release from nerve e
Read More
11/13/2026
A review compares MS with harmful drug reactions and proposes ways to test how immune genes, lasting
Read More
11/13/2026
This review examines how vitamin D and vitamin A signals shape immune activity in MS and other disea
Read More
11/12/2026
In mice with an MS-like disease, a lab-made protein improved movement and thinking. Researchers also
Read More
11/12/2026
A review proposes how the Epstein-Barr virus might contribute to MS. The model brings earlier ideas
Read MoreNot all studies carry the same weight: sample size, study design and whether results were replicated all matter. The credibility score above reflects the journal, and the original paper is linked under More Details. Read how MS Buddy selects and scores research, and talk to your MS care team before acting on any study.
